SEC Filing Summary: Trovagene, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. on May 18, 2016, reporting an event that occurred on May 17, 2016. The registrant is a Delaware corporation headquartered in San Diego, California. Note: The input metadata referenced "Cardiff Oncology, Inc.", but the filing text explicitly identifies the registrant as Trovagene, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes.
Material Changes
The primary material change reported is the appointment of William J. Welch, the Company's Chief Executive Officer, to the Board of Directors.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the standard signature block.
Key Facts for Investor Verification
- William J. Welch was appointed as a director on May 17, 2016.
- William J. Welch concurrently serves as the Chief Executive Officer.
- The filing does not disclose any financial performance data or strategic shifts.